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Abstract
Background: The aim of this study was to assess the reporting of harm in randomized controlled
trials evaluating stents for percutaneous coronary intervention.
Methods: The study design was a methodological systematic review of randomized controlled
trials. The data sources were MEDLINE and the Cochrane Central Register of Controlled Trials.
All reports of randomized controlled trials assessing stent treatment for coronary disease
published between January 1, 2003, and September 30, 2008 were selected.
A standardized abstraction form was used to extract data.
Results:  132 articles were analyzed. Major cardiac adverse events (death, cardiac death,
myocardial infarction or stroke) were reported as primary or secondary outcomes in 107 reports
(81%). However, 19% of the articles contained no data on cardiac events. The mode of data
collection of adverse events was given in 29 reports (22%) and a definition of expected adverse
events was provided in 47 (36%). The length of follow-up was reported in 95 reports (72%).
Assessment of adverse events by an adjudication committee was described in 46 reports (35%),
and adverse events were described as being followed up for 6 months in 24% of reports (n = 32),
between 7 to 12 months in 42% (n = 55) and for more than 1 year in 4% (n = 5). In 115 reports
(87%), numerical data on the nature of the adverse events were reported per treatment arm.
Procedural complications were described in 30 articles (23%). The causality of adverse events was
reported in only 4 articles.
Conclusion:  Several harm-related data were not adequately accounted for in articles of
randomized controlled trials assessing stents for percutaneous coronary intervention.
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Introduction
Since the development of balloon angioplasty and the
introduction of stents for percutaneous coronary interven-
tion, stent technology has rapidly evolved [1]. The tech-
nology now includes bare metal, polymer-coated, drug-
eluting stents and, more recently, biodegradable and bio-
active stents [2].
In fact, the first stent was implanted in humans in 1986,
and by 1999, 84.2% of percutaneous coronary interven-
tions involved stenting [1]. By the end of 2004, drug-elut-
ing stents were used in nearly 80% of percutaneous
coronary interventions in the United States, and within 3
years, several million drug-eluting stents had been
implanted worldwide [1-3].
This widespread dissemination of the technology may
have been achieved at the expense of insufficient assess-
ment of harm [4-7]. Recent reports have highlighted safety
concerns with drug-eluting stents, related to late adverse
clinical events caused by late stent thrombosis [8]. Given
the lack of large-scale randomized clinical trials with long-
term follow-up of sufficient power to analyze clinical effi-
cacy and safety of drug-eluting stents, there is an ongoing
debate regarding the long-term safety of drug-eluting
stents [9-15].
This debate raises the issue of the assessment and report-
ing of harm in randomized controlled trials evaluating
stents [16]. Previous studies have shown that data pertain-
ing to harm are underreported in articles of randomised
controlled trials [17-20]. Further, compared to reports
pertaining to drugs, reports of trials assessing nonphar-
mological treatments more often lack descriptions of
harm [21]. Therefore, we aimed to assess the reporting of
harm in randomized controlled trials evaluating coronary
stents.
Methods
Search strategy and study selection
We identified all reports of RCTs assessing stents that were
published between January 1, 2003, and September 30,
2008. We searched MEDLINE using the PubMed interface
and the Cochrane Central Register of Controlled Trials
(issue 1, 2005) using the terms implantable device OR stents
[Mesh Terms] and cardiovascular disease [Mesh Terms] with
a limitation to clinical trials published in English.
One author assessed the retrieved articles and screened the
titles and abstracts to identify relevant studies. We
included articles only if the study was identified as an
RCT, was published as a full-text article, and assessed
stents for PCI. We excluded case series, uncontrolled stud-
ies, articles published as abstracts only, editorials, news,
correspondence sections, articles not including a com-
plete description of the methods, and trials assessing
other implantable devices (e.g., pacemaker, defibrillator,
or cardiac valve) or stents in other vascular diseases.
Reports of RCTs assessing technical interventions or surgi-
cal procedures where the use of stents was not systemati-
cally required were also excluded. We screened articles for
duplicate publication (ie, the same trial published with
results from different lengths of follow-up), and selected
only the original articles.
Data extraction
From a review of the relevant literature, we generated a
standardized data collection form that was iterated within
the research team [14,15]. Before data extraction, as a cal-
ibration exercise, two members of the team (M.E., I.B.)
independently evaluated a separate set of 20 reports. A
meeting followed in which the ratings were reviewed and
disagreements resolved by consensus. One reviewer
(M.E.) independently completed all data extractions. A
second member of the team (I.B.) reviewed a random
sample of 25 articles as a quality assurance exercise. The
data abstraction form is available upon request.
We collected data on trial characteristics: year of publica-
tion, funding source (public support, manufacturer sup-
port or mixed), number of centers, sample size, main
outcome, experimental treatment (type of stent; specific
procedure of implantation such as intravascular ultra-
sound-guidance, and the control treatment (stent, specific
procedure of stent implantation, surgery, angioplasty,
pharmacological treatments or other treatments).
Gathering data for the reporting of harm involved a sys-
tematic collection of the nature of adverse events, meth-
ods used to collect harm-related information, length of
follow-up, nature and severity of adverse events, adverse
events causally related to treatment, and procedural com-
plications (ie, stent loss, dissection). Since in stent trials,
the main outcome is frequently a composite of cardiac
death, myocardial infarction, revascularisation and/or
stroke (ie, Major Adverse Cardiac Events [MACE] or Major
Adverse Cardiac and (Cerebrovascular) Events
[MAC(C)E]), we checked whether the harm-related data
reported pertained to only MACE or MACCE, or also to
other adverse events such as bleeding.
We also checked whether an adjudication committee eval-
uated adverse events and whether a Data Safety Monitor-
ing Board (DSMB) was reported as being involved in the
oversight of the trial, for patient safety. Data on these
committees included the description of the members,
whether adjudication committees were blinded and
whether specific rules for submitting adverse events to the
committees were reported.Trials 2009, 10:29 http://www.trialsjournal.com/content/10/1/29
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Finally, as recommended by Ioannidis et al., we measured
the space allocated to adverse events in the results sections
(ie, proportion of lines dedicated to reporting adverse
events) to evaluate the quality of reporting harm-related
data [7].
Statistical analysis
Continuous variables are reported with descriptive statis-
tics: mean, standard deviation (SD), median (lower quar-
tile; upper quartile) and minimum and maximum values.
Categorical variables are described with frequencies and
percentages.
The analysis of the space dedicated to the reporting of
harm was evaluated by use of Student's t-test, Wilcoxon
test or Spearman correlation as appropriate for the follow-
ing factors: funding sources (manufacturer vs. public
funding), type of stent (bare metal vs. polymer-coating or
drug-eluting), impact factor of journal, whether the jour-
nal endorsed the CONSORT Statements, and location of
the trials (North America or other countries).
All data analyses involved use of SAS for Windows,
Release 9.1 (SAS Institute, Cary, North Carolina USA).
Results
Selected articles
We screened the titles and abstracts of 867 potentially eli-
gible reports, examined the full text of 255 articles, and
identified 132 studies meeting our inclusion criteria. The
full screening process was previously published [22].
Trial characteristics
The trial characteristics are described in Table 1. In brief,
15% of reports (n = 20) were published in a general med-
ical journal. The median sample size was 389 patients (Q1
to Q3 109.5 – 496.5). Most trials were multicenter (48%,
n = 63). The median number of centers was 15.4 (Q1 to
Q3 1 – 22). However, in one-third of the reports, the
number of centers involved was not reported or was
unclear. The experimental treatment was described as a
bare metal stent in 31% of reports (n = 41), a polymer-
coated stent in 14% (n = 19), a drug-eluting stent in 49%
(n = 64) and a strategy of stent use in 6% (n = 8). The con-
trol treatment was a stent in 67% of reports (n = 88) (bare
metal stents in 61 reports and drug-eluting or polymer-
coated stents in 27), another strategy of stent implanta-
tion in 8% (n = 10), balloon angioplasty in 18% (n = 24)
and coronary artery surgery in 8% (n = 10). The source of
funding was totally or partially private in almost half of
the reports (42%, n = 56) but was not reported in 43% (n
= 57).
Major cardiac adverse events
Major cardiac adverse events (death, cardiac death, myo-
cardial infarction or stroke) were reported as the primary
outcome in only 26% of reports (n = 34), as secondary
outcomes (ie, clearly reported in the methods or in the
results section) in 45% (n = 60) and as both primary and
secondary outcomes in 10% (n = 13). In 19% of reports
(n = 25), no data were provided on the rate of major car-
diac adverse events.
Assessment of harm
The reporting of the methods used to assess harm-related
data is presented in Table 2.
The collection of the nature of adverse events was
described in 83% of reports (n = 110), and the methods
used for collecting data for at least some adverse events
were given in 22% (n = 29). A definition of expected
adverse events was provided in 36% of reports (n = 47),
with a grading system for severity given in 7. Adverse
events were adjudicated by an event committee in 35% of
the reports (n = 46), with the committee membership
described in 50% (n = 23/46) and the assessment of
adverse events by the committee reported as blinded in
78% (n = 36/46). The specific rules for submitting adverse
events to the adjudication committee were given in only
six articles out of 132.
When focusing on adverse events other than cardiac or
cerebrovascular events, (eg. bleeding), the systematic col-
lection of the nature of adverse events and the method of
data collection were provided in only 36% (n = 47) and
12% (n = 16) of reports, respectively.
Length of follow-up
Adverse events were described as being followed up for
less than 1 month in 2% of reports (n = 3), up to 6 months
in 34% (n = 24), between 7 and 12 months in 42% (n =
55) and more than 1 year in 4% (n = 5). However, the
time frame of surveillance for adverse events was not
reported in 22% of reports (n = 29).
Reporting of harm
The reporting of harm-related data is presented in Table 3.
In 87% of reports (n = 87), numerical data on the nature
of adverse events per treatment arm were given. These
details were reported for adverse events other than
MAC(C)E in half of the reports. The severity of adverse
events per arm was reported with numerical data in 86%
of reports (n = 114) but pertained to events other than
MAC(C)E in only 13% (n = 17). Procedural complica-
tions were reported in 23% of articles (n = 30). The cau-
sality of adverse events was given in only 4 articles;
adverse events were attributed to medical gestures during
the implantation procedure.
Data Safety Monitoring Board (DSMB)
A DSMB was described in 14% of the reports (n = 18),
with description of its full membership given in 15 ofTrials 2009, 10:29 http://www.trialsjournal.com/content/10/1/29
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these (83%). The DSMB was described as adjudicating
adverse events in 61% of reports (n = 11/18). In only 8
reports was the DSMB described as evaluating the totality
of adverse events (serious or not). A DSMB was more
often reported in trials assessing drug-eluting stents. The
study sample size was higher in trials reporting than not
reporting a DSMB (mean [SD] 798.3 [462.9] vs. 323.9
[357.9]).
Space allocated to harm reporting within the articles
The mean proportion of space allocated to describing
harm in the results section, the tables and figures, was
24%, 21% and 17%, respectively. The space allotted to
descriptions of harm did not differ according to funding
source, type of stent, journal impact factor or length of fol-
low-up.
Discussion
This study assessed the reporting of harm in published
randomized controlled trials evaluating coronary stents
published over a 6-year period. Our results suggest that
harm-related data receive substantial coverage in these
reports in which major cardiac adverse events are fre-
quently evaluated as primary or secondary outcomes.
However, the reporting of important issues is lacking and
could be improved upon [23].
Although cardiac events are essential outcomes for trials
assessing coronary stents, surprisingly, in 19% of the arti-
cles, data on these events were not reported (although
they may have been collected). Further, the assessment
and reporting of harm mainly focused on cardiac adverse
events and neglected other events such as bleeding.
Table 1: Reports characteristics
n (%)
n = 132
Journal
General medical journal 20 (15.2)
Circulation 15 (11.4)
American Heart Journal 14 (10.6)
Catheter and Cardiovascular Intervention 18 (13.6)
Journal of the American College of Cardiology 17 (12.9)
American Journal of Cardiology 15 (11.4)
Other 33 (25.0)
Funding
Public funding 16 (12.1)
Manufacturer funding 49(37.1)
Both public and manufacturer funding 7 (5.3)
No funding 3 (2.3)
Not reported 57 (43.2)
Interventions
BMS 41 (31.1)
Polymer-coated stent 19 (14.4)
DES 64 (48.5)
Strategy of stent implantation 8 (6.1)
Comparisons (experimental intervention vs control arm)
DES vs BMS 35 (26.5)
DES vs another DES 19 (14.4)
DES vs same DES but with a different dosage 5 (3.8)
DES vs balloon angioplasty 6 (4.5)
DES vs polymer-coated stent 3 (2.3)
DES vs surgery 1 (0.8)
Polymer-coated stent vs BMS 13 (9.8)
Polymer-coated stent vs angioplasty 3 (2.3)
BMS vs another BMS 13 (9.8)
BMS vs angioplasty 10 (7.6)
BMS vs surgery 9 (6.8)
BMS vs a strategy of stent implantation 6 (6.8)
Strategy of stent implantation vs another strategy of stent implantation 4 (3.0)
Strategy of stent implantation vs angioplasty 5 (3.8)
BMS = bare-metal stent
DES = drug-eluting stentTrials 2009, 10:29 http://www.trialsjournal.com/content/10/1/29
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The methods used to collect data on harm and the defini-
tion of expected adverse events were insufficiently
described. Only one third of reports described the evalua-
tion of harm by an adjudication committee, but descrip-
tions of how the committee functioned were lacking.
Nevertheless, perceived differences in the treatment safety
profile may result simply from the use of different meth-
ods or different definitions [17]. Determining whether a
patient has reached a clinical event such as cardiac death
involves some subjectivity [24]. For this reason, the US
Food and Drug Administration and the European Medi-
cine Agency recommend assessing clinical events by adju-
dication committees [25,26]. The importance of such
committees has been outlined in several studies showing
the classification of events changed in about 20% to 30%
of cases after assessment by such a committee [22,27-30].
In addition, we found that the length of follow-up was
short (less than 1 year in most reports), even though many
case reports described late thrombosis occurring more
than 14 or 20 months after implantation [16-18].
Finally, a DSMB was described in only 14% of reports.
Nevertheless, a DSMB is required for clinical trials large
enough to detect important effects in mortality and irre-
Table 2: Assessment of harm described in reports of randomized controlled trials assessing stent treatment for coronary diseases by 
type of stent
All reports Drug-eluting stent Polymer-coating stent Bare metal stent
N = 132 N = 64 N = 19 N = 41
N (%) N (%) N (%) N (%)
Assessment of harm
- Nature of adverse events systematically collected when 
considering
- All adverse events 110 (83) 50 (78) 16 (84) 39 (95)
- Events other than MAC(C)E1 63 (48) 22 (34) 8 (42) 16 (39)
- Mode of data collection provided when considering
- All adverse events 29 (22) 17 (27) 5 (26) 6 (15)
- Events other than MAC(C)E1 13 (10)
Definition of expected adverse event 47 (36) 27 (42) 2 (11) 14 (34)
Assessment by an adjudication committee 46 (35) 35 (55) 4 (21) 7 (17)
Length of follow-up specified 95 (72) 52 (81) 11 (58) 32 (78)
- < 1 month 3 (2) 1 (2) 0 2 (5)
- 6 months 32 (24) 14 (22) 7 (37) 11 (27)
- 7–11 months 27 (20) 21 (33) 1 (5) 5 (12)
- 12 months 28 (21) 14 (22) 1 (5) 13 (32)
- > 12 months 5 (4) 2 (3) 2 (11) 1 (2)
No duration specified 29 (22) 12 (19) 8 (42) 9 (22)
1MAC(C)E: Major Adverse Cardiac (Cerebrovascular) Event
Table 3: Reporting of harm in reports of randomized controlled trials assessing stent treatment for coronary diseases by type of stent
All reports Drug-eluting stent Polymer-coating stent Bare metal stent
N = 132 N = 64 N = 19 N = 41
N (%) N (%) N (%) N (%)
Nature of harm
- Reporting with numerical data per trial arm when considering
- All adverse events 115 (87) 52 (81) 15 (79) 39 (95)
- Events other than MAC(C)E1 66 (50) 32 (50) 8 (42) 20 (49)
Harm severity
- Reporting with numerical data per trial arm when considering
- All adverse events 114 (86) 52 (81) 15 (79) 39 (95)
- Events other than MAC(C)E1 17 (13)
Relation of harm to treatment 4 (3) 2 (3) 1 (5) 1 (2)
Procedural complications 30 (23) 9 (14) 3 (16) 14 (34)
1 MAC(C)E: Major Adverse Cardiac (Cerebrovascular) EventTrials 2009, 10:29 http://www.trialsjournal.com/content/10/1/29
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versible morbidity rates, when the risk of a treatment is
unknown, and when a therapy has a known risk of severe
side effects [31]. These criteria were fulfilled in most of the
trial reports we selected. When a DSMB is planned, certain
information concerning its governance and a monitoring
plan should be provided: the DSMB should be independ-
ent of the sponsor, and its members should not have any
potentially disqualifying conflicts of interest in the out-
come of the trial [32]. Members with appropriate qualifi-
cations for defined roles should be chosen. However, the
functioning of these committees was insufficiently
described in our reports to allow for adequate appraisal.
This study has some limitations. We assessed only reports
of randomized controlled trials, not the trials themselves,
and failure to report is not necessarily equivalent to failure
to actually carry out the procedure. Further, data on the
time frame of surveying adverse events could have been
reported in follow-up studies, but we focused on only the
initial publication of the trial results.
Conclusion
In conclusion, this study highlights that several harm-
related data are not adequately accounted for in initial
published reports of randomized controlled trials, here
trials of stent treatment for coronary diseases.
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